The Cigna Group is a global health services company. The Companys portfolio of offerings solves diverse challenges across the healthcare system. The Company offers a differentiated set of pharmacy, medical, behavioral, dental and supplemental products, and services, primarily through two platforms: Evernorth Health Services and Cigna Healthcare.
Company profile
Ticker
CI
Exchange
Website
CEO
David Cordani
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cigna Corp, Halfmoon Parent, Inc.
SEC CIK
Corporate docs
Subsidiaries
Accredo Health Group, Inc. • Accredo Health, Incorporated • Allegiance Life & Health Insurance Company • American Retirement Life Insurance Company • Ascent Health Services LLC • Bravo Health Mid-Atlantic, Inc. • Bravo Health Pennsylvania, Inc. • Care Continuum, Inc. • CareCore NJ, LLC • Chiro Alliance Corporation ...
CI stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
6 Jun 24
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
The Cigna Group Reports Strong First Quarter 2024 Results, Raises 2024 Outlook
2 May 24
8-K
Submission of Matters to a Vote of Security Holders
26 Apr 24
8-K
Entry into a Material Definitive Agreement
26 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
PX14A6G
Letter to shareholders
11 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEFA14A
Additional proxy soliciting materials
15 Mar 24
ARS
2023 FY
Annual report to shareholders
15 Mar 24
Transcripts
CI
Earnings call transcript
2024 Q1
2 May 24
CI
Earnings call transcript
2023 Q4
2 Feb 24
CI
Earnings call transcript
2023 Q3
2 Nov 23
CI
Earnings call transcript
2023 Q2
3 Aug 23
CI
Earnings call transcript
2023 Q2
3 Aug 23
CI
Earnings call transcript
2023 Q1
5 May 23
CI
Earnings call transcript
2022 Q4
3 Feb 23
CI
Earnings call transcript
2022 Q3
3 Nov 22
CI
Earnings call transcript
2022 Q2
4 Aug 22
CI
Earnings call transcript
2022 Q1
6 May 22
Latest ownership filings
4
George Kurian
4 Jun 24
4
ERIC C WISEMAN
4 Jun 24
4
Noelle K Eder
16 May 24
4
Hoeltzel Mary T Agoglia
16 May 24
144
Notice of proposed sale of securities
14 May 24
144
Notice of proposed sale of securities
14 May 24
144
Notice of proposed sale of securities
9 May 24
144
Notice of proposed sale of securities
3 May 24
4
Philip Ozuah
26 Apr 24
4
ERIC C WISEMAN
26 Apr 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 May 24 | Kurian George | Phantom Stock Units Common Stock, $.01 Par Value | Grant | Acquire A | No | No | 344.62 | 87.052 | 30.00 k | 1,082.26 |
31 May 24 | Eric C Wiseman | Phantom Stock Units Common Stock, $.01 Par Value | Grant | Acquire A | No | No | 344.62 | 114.619 | 39.50 k | 7,909.295 |
15 May 24 | Noelle K Eder | Common Stock, $.01 Par Value | Option exercise | Acquire M | No | Yes | 171.385 | 875 | 149.96 k | 16,699 |
15 May 24 | Noelle K Eder | Employee Stock Option Common Stock, $.01 Par Value | Option exercise | Dispose M | No | Yes | 171.385 | 875 | 149.96 k | 0 |
14 May 24 | Hoeltzel Mary T Agoglia | Common Stock, $.01 Par Value | Sell | Dispose S | No | No | 348.7133 | 5,946 | 2.07 mm | 2,594.738 |
14 May 24 | Hoeltzel Mary T Agoglia | Common Stock, $.01 Par Value | Option exercise | Acquire M | No | No | 120.895 | 5,946 | 718.84 k | 8,540.738 |
14 May 24 | Hoeltzel Mary T Agoglia | Employee Stock Option Common Stock, $.01 Par Value | Option exercise | Dispose M | No | No | 120.895 | 5,946 | 718.84 k | 0 |
14 May 24 | Noelle K Eder | Common Stock, $.01 Par Value | Sell | Dispose S | No | Yes | 348.47 | 10,700 | 3.73 mm | 15,824 |
14 May 24 | Noelle K Eder | Common Stock, $.01 Par Value | Option exercise | Acquire M | No | Yes | 171.385 | 5,533 | 948.27 k | 26,524 |
14 May 24 | Noelle K Eder | Employee Stock Option Common Stock, $.01 Par Value | Option exercise | Dispose M | No | Yes | 171.385 | 5,533 | 948.27 k | 875 |
News
AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability
7 Jun 24
Cigna Expects To Reaffirm Projected FY24 Consolidated Adjusted EPS From Operations Of At Least $28.40; Est $28.29
6 Jun 24
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,700 Today
5 Jun 24
JP Morgan Maintains Overweight on Cigna Group, Raises Price Target to $435
30 May 24
Forecasting The Future: 12 Analyst Projections For Cigna Group
30 May 24
Press releases
Express Scripts enhances strategies to support access to care at independent pharmacies
23 May 24
The Cigna Group Ranks No. 7 in Fair360 Top 50 Companies
14 May 24
The Cigna Group Reports Strong First Quarter 2024 Results, Raises 2024 Outlook
2 May 24
New Report: Employers Play Critical Role in Curbing Today's Youth Mental Health Crisis
26 Apr 24
Evernorth announces Humira biosimilar available at $0 out of pocket for Accredo patients in June
25 Apr 24